Published in Am J Transl Res on September 15, 2017
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats. Am J Physiol (1997) 2.98
Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med (1989) 2.21
Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes (2003) 2.16
Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol (2008) 1.73
Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol (1995) 1.73
Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis (2005) 1.71
Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase. Kidney Int (2010) 1.67
Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess (2005) 1.51
Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest (2002) 1.44
Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol (2012) 1.42
Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes (1994) 1.40
Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care (2011) 1.39
Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models. Am J Physiol Endocrinol Metab (2009) 1.34
Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med (2006) 1.31
Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila) (2011) 1.25
Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients. Diabetes Res Clin Pract (2012) 1.21
Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol (2012) 1.19
A genetic defect in beta-cell gene expression segregates independently from the fa locus in the ZDF rat. Diabetes (2001) 1.12
Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol (2007) 1.12
A new obesity-prone, glucose-intolerant rat strain (F.DIO). Am J Physiol Regul Integr Comp Physiol (2003) 1.07
Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev (2012) 1.06
Reduction of proteinuria with angiotensin receptor blockers. Nat Clin Pract Cardiovasc Med (2008) 1.01
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int (2000) 1.00
Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol (1996) 0.97
Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats. Ren Fail (2000) 0.96
Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care (2013) 0.95
Glycation as the glucose link to diabetic complications. J Am Osteopath Assoc (2000) 0.94
Renal and metabolic effects of tempol in obese ZSF1 rats--distinct role for superoxide and hydrogen peroxide in diabetic renal injury. Metabolism (2008) 0.93
Renal glucose reabsorption during hypertonic glucose infusion in female streptozotocin-induced diabetic rats. Life Sci (2001) 0.93
Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm (2014) 0.93
2-Methoxyestradiol and 2-ethoxyestradiol retard the progression of renal disease in aged, obese, diabetic ZSF1 rats. J Cardiovasc Pharmacol (2007) 0.93
Proximal tubule dysfunction is dissociated from endothelial dysfunction in normoalbuminuric patients with type 2 diabetes mellitus: a cross-sectional study. Nephron Clin Pract (2010) 0.91
Renal injury: similarities and differences in male and female rats with the metabolic syndrome. Kidney Int (2006) 0.91
An Update on the Use of Animal Models in Diabetic Nephropathy Research. Curr Diab Rep (2016) 0.89
Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Hypertension (2014) 0.88
Sensitive and early markers of renal injury: where are we and what is the way forward? Toxicol Sci (2010) 0.88
Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients. Biomark Res (2015) 0.87
Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol (2011) 0.87
Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus. Drugs (1997) 0.86
Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol (2005) 0.86
Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms. Trends Endocrinol Metab (2016) 0.85
Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev (2016) 0.84
Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. Int Urol Nephrol (2015) 0.84
Promotion of cell proliferation by clusterin in the renal tissue repair phase after ischemia-reperfusion injury. Am J Physiol Renal Physiol (2014) 0.83
Challenges and issues with streptozotocin-induced diabetes - A clinically relevant animal model to understand the diabetes pathogenesis and evaluate therapeutics. Chem Biol Interact (2015) 0.82
Early renal injury induced by caffeine consumption in obese, diabetic ZSF1 rats. Ren Fail (2007) 0.82
SGLT2 Inhibitors and the Diabetic Kidney. Diabetes Care (2016) 0.82
Factors associated with remission and/or regression of microalbuminuria in type 2 diabetes mellitus. Acta Med Okayama (2014) 0.81
Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease. J Diabetes Res (2016) 0.81
A study of the prevalence of significant increases in serum creatinine following angiotension-converting enzyme inhibitor administration. J Hum Hypertens (2005) 0.80
KDIGO 2012 Clinical Practice Guideline CKD classification rules out creatinine clearance 24 hour urine collection? Clin Biochem (2015) 0.80
Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy. J Diabetes Investig (2014) 0.80
Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats. Biomed Rep (2013) 0.80
Characterization of the ZDSD Rat: A Translational Model for the Study of Metabolic Syndrome and Type 2 Diabetes. J Diabetes Res (2015) 0.80
Complication in diabetic nephropathy. Diabetes Metab Syndr (2016) 0.80
Combined Association of Serum Uric Acid and Metabolic Syndrome with Chronic Kidney Disease in Hypertensive Patients. Kidney Blood Press Res (2016) 0.79
Characterization of diabetic neuropathy in the Zucker diabetic Sprague-Dawley rat: a new animal model for type 2 diabetes. J Diabetes Res (2014) 0.79
Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats. Am J Physiol Renal Physiol (2014) 0.79
Value of the intrarenal arterial resistivity indices and different renal biomarkers for early identification of diabetic nephropathy in type 1 diabetic patients. J Pediatr Endocrinol Metab (2016) 0.79
Visceral adiposity syndrome. Diabetol Metab Syndr (2016) 0.79
Therapeutic angiogenesis by vascular endothelial growth factor supplementation for treatment of renal disease. Curr Opin Nephrol Hypertens (2016) 0.78
Association of blood glucose level and hypertension in Elderly Chinese Subjects: a community based study. BMC Endocr Disord (2016) 0.78
Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy. J Diabetes Res (2016) 0.78
Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats. Physiol Rep (2015) 0.77
Obesity, immunomodulation and chronic kidney disease. Curr Opin Pharmacol (2013) 0.77
Exogenous kallikrein protects against diabetic nephropathy. Kidney Int (2016) 0.76
Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes. Drug Des Devel Ther (2015) 0.76
Effect of Type 2 Diabetes Mellitus and Diabetic Nephropathy on IgG Pharmacokinetics and Subcutaneous Bioavailability in the Rat. AAPS J (2015) 0.76
Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies. Curr Drug Metab (2016) 0.76
Effective antihypertensive strategies for high-risk patients with diabetic nephropathy. J Investig Med (2010) 0.76
The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc (2005) 0.76
The Short-Term Remission of Diabetic Nephropathy After Roux-en-Y Gastric Bypass in Chinese Patients of T2DM with Obesity. Obes Surg (2015) 0.76
Nigella sativa oil and thymoquinone ameliorate albuminuria and renal extracellular matrix accumulation in the experimental diabetic rats. Eur Rev Med Pharmacol Sci (2016) 0.76
Exogenously administered adenosine attenuates renal damage in streptozotocin-induced diabetic rats. Ren Fail (2016) 0.76
[Impact of glycogen synthase kinase-3β (GSK-3β) inhibitor on Wnt and NF-κB signal pathways in a rat model of diabetic nephropathy]. Zhonghua Bing Li Xue Za Zhi (2015) 0.75
[Prevalence of chronic kidney disease and its risk factors in subjects with different glucose metabolism status]. Nan Fang Yi Ke Da Xue Xue Bao (2016) 0.75
Improvement in glomerular filtration rate may decrease mortality among type-2 diabetics with chronic kidney disease lacking proteinuria: A retrospective study. Saudi J Kidney Dis Transpl (2015) 0.75
Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. J Investig Med (2016) 0.75
Changes in the Fracture Resistance of Bone with the Progression of Type 2 Diabetes in the ZDSD Rat. Calcif Tissue Int (2016) 0.75
Involvement of the NF-κB signaling pathway in the renoprotective effects of isorhamnetin in a type 2 diabetic rat model. Biomed Rep (2016) 0.75
Hydrogen Sulfide Mitigates Kidney Injury in High Fat Diet-Induced Obese Mice. Oxid Med Cell Longev (2016) 0.75
Reduction of mean arterial pressure and proteinuria by the effect of ACEIs (Lisinopril) in Kurdish hypertensive patients in Hawler City. Glob J Health Sci (2012) 0.75
Histone Acetylation and Its Modifiers in the Pathogenesis of Diabetic Nephropathy. J Diabetes Res (2016) 0.75
Review: in type 2 diabetes, GLP-1 agonists plus basal insulin reduce HbA1c without increasing hypoglycemia. Ann Intern Med (2015) 0.75
Wound Healing Delay in the ZDSD Rat. In Vivo (2017) 0.75
Diagnostic value of cystatin C for diagnosis of early renal damages in type 2 diabetic mellitus patients: The first experience in Iran. J Res Med Sci (2015) 0.75
Effect of fosinopril on chemerin and VEGF expression in diabetic nephropathy rats. Int J Clin Exp Pathol (2015) 0.75